$NXTC
NextCure, Inc.

2021 Q4 Form 10-K Financial Statement

#000155837022002824 Filed on March 03, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.807M $20.57M $4.130M
YoY Change 16.39% 20.66% 57.63%
% of Gross Profit
Research & Development $12.26M $50.19M $12.11M
YoY Change 1.27% 7.81% 6.23%
% of Gross Profit
Depreciation & Amortization $2.103M $4.300M $990.0K
YoY Change 112.42% 26.47% 30.26%
% of Gross Profit
Operating Expenses $17.07M $70.77M $16.24M
YoY Change 5.12% 11.26% 15.83%
Operating Profit -$70.77M
YoY Change 71.66%
Interest Expense $132.0K $1.376M $780.0K
YoY Change -83.08% -70.22% -27.78%
% of Operating Profit
Other Income/Expense, Net $1.376M
YoY Change -70.23%
Pretax Income -$16.94M -$69.39M -$15.46M
YoY Change 9.57% 89.59% 41.45%
Income Tax
% Of Pretax Income
Net Earnings -$16.94M -$69.39M -$15.46M
YoY Change 9.57% 89.57% 41.45%
Net Earnings / Revenue
Basic Earnings Per Share -$2.51
Diluted Earnings Per Share -$607.3K -$2.51 -$561.0K
COMMON SHARES
Basic Shares Outstanding 27.63M 27.62M
Diluted Shares Outstanding 27.62M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $219.6M $219.6M $283.4M
YoY Change -22.53% -22.52% -15.29%
Cash & Equivalents $12.34M $12.34M $32.77M
Short-Term Investments $207.3M $207.3M $250.7M
Other Short-Term Assets $8.226M $8.226M $4.500M
YoY Change 82.8% 82.8% -16.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $227.8M $227.8M $288.0M
YoY Change -20.89% -20.9% -15.3%
LONG-TERM ASSETS
Property, Plant & Equipment $13.99M $13.99M $15.81M
YoY Change -11.49% -11.44% 30.65%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $577.0K $577.0K $2.857M
YoY Change -79.8% -80.1% -30.32%
Total Long-Term Assets $14.57M $14.57M $18.67M
YoY Change -21.95% -21.67% 15.22%
TOTAL ASSETS
Total Short-Term Assets $227.8M $227.8M $288.0M
Total Long-Term Assets $14.57M $14.57M $18.67M
Total Assets $242.4M $242.4M $306.6M
YoY Change -20.96% -20.94% -13.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.942M $1.942M $3.901M
YoY Change -50.22% -50.21% 105.32%
Accrued Expenses $4.449M $4.449M $4.627M
YoY Change -3.85% -3.28% -5.57%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $1.667M
YoY Change -100.0% -100.0% -1.94%
Total Short-Term Liabilities $6.608M $6.608M $10.33M
YoY Change -36.0% -35.84% -31.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $1.806M
YoY Change -100.0% -100.0% -45.27%
Other Long-Term Liabilities $2.392M $2.392M $800.0K
YoY Change 199.0% 199.0% -95.09%
Total Long-Term Liabilities $2.392M $2.392M $1.806M
YoY Change 32.45% -8.0% -90.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.608M $6.608M $10.33M
Total Long-Term Liabilities $2.392M $2.392M $1.806M
Total Liabilities $9.000M $9.000M $12.92M
YoY Change -30.36% -30.23% -62.76%
SHAREHOLDERS EQUITY
Retained Earnings -$187.0M -$117.6M
YoY Change 58.99%
Common Stock $28.00K $28.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $233.4M $233.4M $293.7M
YoY Change
Total Liabilities & Shareholders Equity $242.4M $242.4M $306.6M
YoY Change -20.96% -20.94% -13.91%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$16.94M -$69.39M -$15.46M
YoY Change 9.57% 89.57% 41.45%
Depreciation, Depletion And Amortization $2.103M $4.300M $990.0K
YoY Change 112.42% 26.47% 30.26%
Cash From Operating Activities -$13.45M -$57.24M -$6.270M
YoY Change 114.5% 27.34% -37.24%
INVESTING ACTIVITIES
Capital Expenditures -$825.0K $2.360M -$980.0K
YoY Change -15.82% -66.91% 20.99%
Acquisitions
YoY Change
Other Investing Activities -$10.18M $38.96M $17.48M
YoY Change -158.22% -23.09% -113.84%
Cash From Investing Activities -$11.00M $36.60M $16.49M
YoY Change -166.71% -15.9% -112.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 123.0K -3.265M -400.0K
YoY Change -130.75% 130.74% -100.25%
NET CHANGE
Cash From Operating Activities -13.45M -57.24M -6.270M
Cash From Investing Activities -11.00M 36.60M 16.49M
Cash From Financing Activities 123.0K -3.265M -400.0K
Net Change In Cash -24.33M -23.91M 9.820M
YoY Change -347.73% 740.06% -59.34%
FREE CASH FLOW
Cash From Operating Activities -$13.45M -$57.24M -$6.270M
Capital Expenditures -$825.0K $2.360M -$980.0K
Free Cash Flow -$12.62M -$59.60M -$5.290M
YoY Change 138.64% 14.43% -42.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#TechnologyServiceMember
CY2021 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#TechnologyServiceMember
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.51
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.33
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27615977
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27532177
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27680997
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001661059
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27568802
CY2020Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27680997
CY2019Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1245
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-38905
CY2021 dei Entity Registrant Name
EntityRegistrantName
NextCure, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-5231247
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
9000 Virginia Manor Road, Suite 200
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Beltsville
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20705
CY2021 dei City Area Code
CityAreaCode
240
CY2021 dei Local Phone Number
LocalPhoneNumber
399-4900
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
NXTC
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
209000000.0
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27724303
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Baltimore, MD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12337000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32772000
CY2021Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
207254000
CY2020Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
250676000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
39000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1706000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8187000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2824000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
227817000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
287978000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13992000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15809000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
577000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2857000
CY2021Q4 us-gaap Assets
Assets
242386000
CY2020Q4 us-gaap Assets
Assets
306644000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1942000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3901000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4449000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4627000
CY2021Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
217000
CY2020Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
130000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1667000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6608000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10325000
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2392000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
792000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1806000
CY2021Q4 us-gaap Liabilities
Liabilities
9000000
CY2020Q4 us-gaap Liabilities
Liabilities
12923000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27680997
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27568802
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
421047000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
410551000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-663000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
779000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-187026000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117637000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
233386000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
293721000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
242386000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
306644000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22378000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50192000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46554000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20573000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17049000
CY2021 us-gaap Operating Expenses
OperatingExpenses
70765000
CY2020 us-gaap Operating Expenses
OperatingExpenses
63603000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-70765000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-41225000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1376000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4622000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-69389000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-36603000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.51
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.33
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27615977
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27532177
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-69389000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-36603000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1442000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
779000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70831000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35824000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
321484000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7911000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
112000
CY2020 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2020 nxtc Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Adjusted
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
817000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-36603000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
293721000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10288000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
208000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021 nxtc Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Adjusted
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
-1442000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-69389000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
233386000
CY2021 us-gaap Profit Loss
ProfitLoss
-69389000
CY2020 us-gaap Profit Loss
ProfitLoss
-36603000
CY2021 nxtc Depreciation Depletion And Amortization And Other
DepreciationDepletionAndAmortizationAndOther
7196000
CY2020 nxtc Depreciation Depletion And Amortization And Other
DepreciationDepletionAndAmortizationAndOther
3413000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
10288000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
7911000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4889000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-559000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1959000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2040000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-178000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-244000
CY2021 nxtc Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
1687000
CY2020 nxtc Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
348000
CY2020 nxtc Increase Decrease In Deferred Revenue From Related Party
IncreaseDecreaseInDeferredRevenueFromRelatedParty
-22378000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57244000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44954000
CY2021 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
195438000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
187784000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
156477000
CY2020 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
137129000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2360000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7132000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
36601000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43523000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
208000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
112000
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
3473000
CY2020 us-gaap Repayments Of Debt
RepaymentsOfDebt
1527000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3265000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1415000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23908000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2846000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36284000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39130000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12376000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36284000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
162000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
130000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
109000
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15560569
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4077192
CY2019Q4 us-gaap Share Price
SharePrice
36.75
CY2019Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
611578
CY2019Q4 us-gaap Share Price
SharePrice
36.75
CY2019Q4 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
160900000
CY2019Q4 nxtc Payments Of Underwriting Discounts And Commissions
PaymentsOfUnderwritingDiscountsAndCommissions
10300000
CY2019Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1000000.0
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p>
CY2021Q3 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-2400000
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5000000.0
CY2021Q4 nxtc Required Reserve Restricted Cash Current
RequiredReserveRestrictedCashCurrent
0
CY2021Q4 nxtc Required Reserve Restricted Cash Current
RequiredReserveRestrictedCashCurrent
0
CY2020Q4 nxtc Required Reserve Restricted Cash Current
RequiredReserveRestrictedCashCurrent
3500000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12337000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32772000
CY2021Q4 nxtc Restricted Cash Other Assets Non Current
RestrictedCashOtherAssetsNonCurrent
0
CY2020Q4 nxtc Restricted Cash Other Assets Non Current
RestrictedCashOtherAssetsNonCurrent
1806000
CY2021Q4 nxtc Restricted Cash And Other Assets Current
RestrictedCashAndOtherAssetsCurrent
39000
CY2020Q4 nxtc Restricted Cash And Other Assets Current
RestrictedCashAndOtherAssetsCurrent
3512000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12376000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36284000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </p>
CY2020 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
207917000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
666000
CY2021Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
207254000
CY2020Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
249897000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
854000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
75000
CY2020Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
250676000
CY2021 us-gaap Marketable Securities Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments
0
CY2021 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
57000
CY2020 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
70000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
104959000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
104775000
CY2021Q4 nxtc Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost
102958000
CY2021Q4 nxtc Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
102479000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
207917000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
207254000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26729000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24369000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12737000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8560000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13992000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15809000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4300000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3400000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1316000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
6537000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11427000
CY2021 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2020 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
900000
CY2020Q4 nxtc Accrued Construction In Progress Current
AccruedConstructionInProgressCurrent
109000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1751000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
973000
CY2021Q4 nxtc Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
727000
CY2020Q4 nxtc Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1744000
CY2021Q4 nxtc Accrued Sponsored Research Expense Current
AccruedSponsoredResearchExpenseCurrent
1315000
CY2020Q4 nxtc Accrued Sponsored Research Expense Current
AccruedSponsoredResearchExpenseCurrent
472000
CY2021Q4 nxtc Accrued Operating Expenses Current
AccruedOperatingExpensesCurrent
656000
CY2020Q4 nxtc Accrued Operating Expenses Current
AccruedOperatingExpensesCurrent
1316000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4449000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4627000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1172000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1171000
CY2021Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1231000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
0
CY2016Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1000000.0
CY2019Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
5000000.0
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27680997
CY2021 nxtc Number Of Votes Per Share
NumberOfVotesPerShare
1
CY2021 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10300000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7900000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
23300000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10288000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7911000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7969
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4545794
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3112376
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.065
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.065
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.032
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.073
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.018
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.020
CY2021 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.285
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.329
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
44451000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
28511000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8862000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6874000
CY2021Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
170000
CY2020Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
306000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3184000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1783000
CY2021Q4 nxtc Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
1121000
CY2020Q4 nxtc Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
635000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
57788000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
38109000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
57705000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
37552000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
83000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
557000
CY2021Q4 nxtc Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
83000
CY2020Q4 nxtc Deferred Tax Liabilities Depreciation And Amortization
DeferredTaxLiabilitiesDepreciationAndAmortization
342000
CY2020Q4 us-gaap Deferred Tax Liabilities Unrealized Gains On Trading Securities
DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
215000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
83000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
557000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
20200000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
160900000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
163400000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
138200000
CY2021Q4 nxtc Deferred Tax Assets Tax Credit Carryforwards Research And Development Federal
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal
8700000
CY2021Q4 nxtc Deferred Tax Assets Tax Credit Carryforwards Research And Development State
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState
100000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0

Files In Submission

Name View Source Status
0001558370-22-002824-index-headers.html Edgar Link pending
0001558370-22-002824-index.html Edgar Link pending
0001558370-22-002824.txt Edgar Link pending
0001558370-22-002824-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nxtc-20211231.xsd Edgar Link pending
nxtc-20211231x10k.htm Edgar Link pending
nxtc-20211231x10k005.jpg Edgar Link pending
nxtc-20211231x10k006.jpg Edgar Link pending
nxtc-20211231x10k007.jpg Edgar Link pending
nxtc-20211231x10k008.jpg Edgar Link pending
nxtc-20211231x10k009.jpg Edgar Link pending
nxtc-20211231x10k010.jpg Edgar Link pending
nxtc-20211231x10k_htm.xml Edgar Link completed
nxtc-20211231xex10d23.htm Edgar Link pending
nxtc-20211231xex10d24.htm Edgar Link pending
nxtc-20211231xex10d24001.jpg Edgar Link pending
nxtc-20211231xex10d25.htm Edgar Link pending
nxtc-20211231xex10d25001.jpg Edgar Link pending
nxtc-20211231xex10d26.htm Edgar Link pending
nxtc-20211231xex10d26001.jpg Edgar Link pending
nxtc-20211231xex23d1.htm Edgar Link pending
nxtc-20211231xex31d1.htm Edgar Link pending
nxtc-20211231xex31d2.htm Edgar Link pending
nxtc-20211231xex32d1.htm Edgar Link pending
nxtc-20211231_cal.xml Edgar Link unprocessable
nxtc-20211231_def.xml Edgar Link unprocessable
nxtc-20211231_lab.xml Edgar Link unprocessable
nxtc-20211231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending